• Welcome, Guest. Please login or register.
    April 05, 2020, 08:14:37 PM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:

thalpal.com

Click to visit us on Facebook


If you have any problems registering or signing in, please send an email to: andythalpal@yahoo.com
Please do not send questions about thalassemia to this address.


Administrators
Andy
Danielle

Thalassemia Patients and Friends and thalpal Ā© A. Battaglia 2019





55248 Posts in 5898 Topics by 6188 Members
Latest Member: jcemanuele

Forum Tip: 
You can change your member name in your profile, under "Account Related Settings," so you don't have to re-register to change it.
« previous next »
Pages: 1 Go Down Print
Author Topic: Bluebird Bio  (Read 4954 times)
Sharmin
Global Moderator
Supreme Member
*****
Offline Offline

Location: Canada

Gender: Female
Posts: 4155


Little A


« on: November 14, 2013, 10:32:51 AM »

This video is very interesting - and tells us all that gene therapy is not just science fiction anymore - it has arrived. 

http://www.youtube.com/watch?v=5Zk9WqYD9nA

A few interesting things to note near the end of the video, if I'm not mistakened he says - myeloablation or myelosuppression depending on how well the procedure works.  Which tells me HOPEFULLY - that Bluebird will take Sloan Kettering's lead and lean toward myelosuppression whenever possible.  Also, his last comment was - hopefully soon they will be able to do gene editing - which makes me think of Crispr and nanotechnology. 

The future is bright - patients - maintain good hemoglobins and keep your iron low - within the normal range if possible!!  Be in the best shape possible to take advantage of all of the promising treatments awaiting you. 

Logged

Sharmin
catchR
Active Member
**
Offline Offline

Posts: 88


« Reply #1 on: May 21, 2014, 11:56:13 PM »

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that bluebird bio and its clinical investigator plan to provide an oral presentation on the HGB-205 Study in beta-thalassemia major patients at the 19th Annual Congress of the European Hematology Association (EHA) in Milan, Italy from June 12-15, 2014.

Abstract Title: Outcomes of gene therapy for beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral beta globin vector.

Lead Author: Marina Cavazzana, M.D.

Session Title: Simultaneous Sessions & EHA Advocacy Sessions

Presentation Date/Time: Saturday, June 14 from 4:15 pm CET to 4:30 pm CET (10:15 am EDT to 10:30 am EDT)

Summary of Abstract Data and Clinical Data to be Presented at EHA:

Clinical data will be presented on two subjects with beta-thalassemia major (#1201 and #1202) transplanted with new lentiviral vector BB305 in the HGB-205 Study
Vector copy number in the drug product for subjects 1201 and 1202 are 1.5 and 2.1 respectively; higher than the drug product vector copy numbers reported in the prior LG001 Study (0.3-0.6), which used the older lentiviral vector HPV569
A detailed update on the clinical data and transfusion status of subjects 1201 and 1202 will be provided as part of the EHA presentation

http://www.streetinsider.com/Corporate+News/Bluebird+Bio+(BLUE)+to+Present+Clinical+Data+From+its+HGB-205+Study/9513611.html
Logged
Canadian_Family
Supreme Member
*****
Offline Offline

Posts: 1064



« Reply #2 on: May 22, 2014, 10:57:04 AM »

Thanks for sharing.

This puts pressure on Memorial Sloan Kettering Cancer Center to come with their study results. However, don't forget that Blue is listed on NASDAQ (companies sometime do these gimmicks to improve the share prices).

Lets hope they have substantial news for the thal community.
Logged

Regards.
Sharmin
Global Moderator
Supreme Member
*****
Offline Offline

Location: Canada

Gender: Female
Posts: 4155


Little A


« Reply #3 on: May 23, 2014, 09:58:24 AM »

thank you for sharing. 

I agree CF - I'm cautiously optimistic...

Logged

Sharmin
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!